Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - December 2012

Tablet Process Development and Validation and the application of QbD (3 day)

11 Dec 2012 - 13 Dec 2012 - County House, 221-241 Beckenham Road, Beckenham, BR3 4UF, Nr London

Bookmark and Share

This interactive workshop provides up-to-date, relevant and detailed information on the impact of Quality by Design (QbD) on the Development and Validation of tablet manufacturing processes. It will also study the identification and evaluation of Critical Product Attributes and Critical Process Parameters for tablets, and their implications for process control. We develop new concepts including the use of risk and process matrices for risk management. The latest ICH and FDA guidance on Quality by Design and Process Development, published in 2009, will be comprehensively reviewed. The hands-on workshop day will enable you to experience at first hand the impact of processing parameters on product quality.

By the end of the course, you will

·         Understand the relationship between the principles of QbD and tablet development and process validation in generic and new product development

·         Understand the relationship between material properties, formulation development and process development

·         Understand the processes commonly used to manufacture tablets and the factors which affect them. Recognise how to identify critical processing parameters, and how to incorporate into a process validation program

·         Understand the principles of PAT, how and where it can be most effectively deployed

·         Know the latest FDA thinking on Process Development including the three key steps of validation

·         Gain practical hands on experience of the impact of processing parameters on product quality on the small scale.

       Who should attend?
The  course  is designed  for people new  to Process Development,  and  those  requiring  a
refresher in the area.  It will also benefit Process Development experts wishing to extend
their understanding of why products processes can go wrong, and regulatory and quality
personnel who need to understand the development process better.  The course will include the latest FDA guidance on the development of generic products under QbD.

       Course outline:
Day 1: 
Morning - Product development 
• Principles of Quality by Design and the product development process 
• Linking material properties to formulation and processing behaviour 
• FDA Guidance on Process Validation 
Workshop session - Understanding Quality by Design 
  Afternoon -
Mixing, and dry granulation 
• Identifying potential Critical Process Parameters. 
• Unit processes 1 - Mixing and blending 
• Assessing blend uniformity. Sampling problems and practice 
Workshop session - blend assessment practical. Effect of material properties on    powder
 mixing behaviour 
Day 2: 
Morning - EFPIA Case study. Wet granulation 
• The new regulatory landscape. Q8, Q9 and Q10 and their impact on product and
process development. 
• EFPIA case study  -  what would a QbD regulatory submission look like? 
• Use of Process Matrices in process development 
• Developing wet granulation processes 
• Granulation endpoint control 
  Afternoon -
Drying, compression and film coating 
• Drying  -  techniques and process control 
• Compression  -  opportunities and threats! 
• Developing film coating processes 
• Round-up session 
Day 3: Practical 
• Blending 
• Granulation 
• Drying 
• Milling 
• Sieving 
• Compression 
• Granule and product characterisation 
Wherever possible participants should bring practical problems and examples which can
be reviewed on the course. The course will be highly participative and useful for people
with or without experience. Numbers are restricted to guarantee personal involvement.    

Ful  Course Speakers
Dr Michael Gamlen is Managing Director of Pharmaceutical Development Services Ltd, 
a pharmaceutical consultancy based in Nottingham (UK).

       Dr Dipankar Dey, PharmaTraining Ltd - Dipankar Dey recently joined PharmaTraining Ltd as Training Manager.

        Full Fee: 3 day course £1770.00 (+ VAT £354.00 if applicable, see notes on VAT)  

Discount of 10% applies for booking 8 weeks in advance. Discount of 10% applies for booking more than 1 delegate. Discount of 10% applies for booking more than 1 course.

Maximum discount received is 15%


Further information
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos